Tarsa Therapeutics, Inc.

Quick facts

Phase 3 pipeline

• Oral Calcitonin Tablets · Bone metabolism / Osteoporosis
  Oral calcitonin activates calcitonin receptors on osteoclasts to inhibit bone resorption and reduce bone loss.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Tarsa Therapeutics, Inc. portfolio CI brief
• Tarsa Therapeutics, Inc. pipeline updates RSS